I lead an interdisciplinary research program that is specifically aimed at the goal of improving health outcomes for patients with infectious diseases including HIV and HCV, substance use disorders, and other vulnerable populations. My research, which uses clinical epidemiology, health economics, simulation modeling, and cost-effectiveness, informs clinical-decision making and health policy to answer clinically- and policy-relevant questions. I am engaged in research using these innovative methods to help understand the impact of and improve upon policies that affect people who use drugs infected with or at high risk for infections. My research is currently been funded by NIDA in the form of both a K01 and a DP2 award as well as multiple grants for which I am a Co-Investigator. I have also received NIAID, the Providence/Boston Center for AIDS Research (CFAR), the BU-CTSI, and the MGH Executive Committee on Research Fund for Medical Discovery. I currently serve as Director of the Health Economics and Modeling Core for the Massachusetts HEALing Communities Study, an NIH-funded grant to significantly reduce overdose. I am the previous recipient of the Charles A. King Trust Research Award, and the prestigious AAMC Herbert W. Nickens Faculty Fellowship Award, which recognizes a junior faculty member who demonstrates leadership potential in addressing inequity in health care. I have published my work and editorials in leading journals such as NEJM, Lancet Public Health, JAMA Internal Medicine, AJPH, Addiction, Clinical Infectious Diseases, and Annals of Internal Medicine. My work has been widely cited in the media, including the Boston Globe, U.S. News and World Report, and NPR.
- George Washington University School of Medicine, MD
- Washington University in St. Louis, BA
- Published on 8/24/2022
Barocas JA, Savinkina A, Lodi S, Epstein RL, Bouton TC, Sperring H, Hsu HE, Jacobson KR, Schechter-Perkins EM, Linas BP, White LF. Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study. Clin Infect Dis. 2022 Aug 24; 75(1):e1112-e1119. PMID: 34499124.
- Published on 6/26/2022
Wheeler A, Valerio H, Cunningham EB, Martinello M, Barocas JA, Colledge-Frisby S, Treloar C, Amin J, Henderson C, Read P, Matthews GV, Dunlop AJ, Gorton C, Hayllar J, Alavi M, Murray C, Marks P, Silk D, Degenhardt L, Dore GJ, Grebely J. Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study. Drug Alcohol Depend. 2022 Aug 01; 237:109543. PMID: 35772249.
- Published on 4/25/2022
Barocas JA, Gai MJ, Nurani A, Bagley SM, Hadland SE. Initiation of HIV pre-exposure prophylaxis among youth in the United States, 2015-2018. AIDS Care. 2022 Apr 25; 1-6. PMID: 35468009.
- Published on 4/14/2022
Bettano A, Del Pozo B, Bernson D, Barocas JA. Stimulant-related incident surveillance using emergency medical service records in Massachusetts, 2013-2020. Drug Alcohol Depend. 2022 Jun 01; 235:109460. PMID: 35468556.
- Published on 4/12/2022
Savinkina A, Madushani RWMA, Eftekhari Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. Addiction. 2022 Sep; 117(9):2450-2461. PMID: 35315162.
- Published on 4/8/2022
Keyes KM, Rutherford C, Hamilton A, Barocas JA, Gelberg KH, Mueller PP, Feaster DJ, El-Bassel N, Cerdá M. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022 Jun; 3. PMID: 35783994.
- Published on 4/3/2022
Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. Addiction. 2022 Oct; 117(10):2635-2648. PMID: 35315148.
- Published on 3/7/2022
Sinha P, Barocas JA. Cost-effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price. Alzheimers Dement (N Y). 2022; 8(1):e12256. PMID: 35282659.
- Published on 2/1/2022
Adams JW, Savinkina A, Hudspeth JC, Gai MJ, Jawa R, Marks LR, Linas BP, Hill A, Flood J, Kimmel S, Barocas JA. Simulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use-Associated Infective Endocarditis. JAMA Netw Open. 2022 02 01; 5(2):e220541. PMID: 35226078.
- Published on 1/31/2022
Zielinski MJ, Praseuth A, Gai MJ, Evans LJ, Zaller ND, Umar I, Barocas JA. Crisis stabilization units for jail diversion: A preliminary assessment of patient characteristics and outcomes. Psychol Serv. 2022 Jan 31. PMID: 35099227.
View 67 more publications: View full profile at BUMC